![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
01 Mylan AB (1)
02 VIIV HEALTHCARE UK LTD (5)
03 ViiV Healthcare GmbH (3)
04 ViiV Healthcare UK Ltd. (3)
01 Abacavir (5)
02 Abacavir; Lamivudine (2)
03 Abacavir; Lamivudine; Zidovudine (1)
04 Dolutegravir; Abacavir; Lamivudine (1)
05 Lamivudine; Abacavir (2)
06 Lamivudine; Abacavir; Dolutegravir (1)
01 Italy (5)
02 Norway (4)
03 Switzerland (3)
01 Abacavir 20Mg/Ml 240Ml Oral Use (1)
02 Abacavir 300Mg 60 Units Oral Use (1)
03 Abacavir+Lamivudine + Zidovudine 300+150+300Mg 60 Units Oral Use (1)
04 Abacavir+Lamivudine 600+300Mg 30 Joined' Oral Use (1)
05 Antic-calc Tablet, Film Coated (4)
06 Dolutegravir+Abacavir+Lamivudine 50+600+300Mg 30 Joined' Oral Use (1)
07 Film Tablet (1)
08 Solution (1)
09 Tablet (1)